Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

Core Viewpoint - Perspective Therapeutics, Inc. announced that updated data on its [Pb]VMT-α-NET program will be presented at the AACR Annual Meeting 2026, highlighting the company's ongoing efforts in developing advanced cancer treatments [1] Group 1: Presentation Details - The poster presentation will feature safety and preliminary efficacy results from dose finding cohorts of the [Pb]VMT-α-NET program, specifically targeting advanced SSTR2+ neuroendocrine tumors [2] - The presentation is scheduled for April 20, 2026, from 9:00 am to 12:00 pm [2] Group 2: About [Pb]VMT-α-NET - [Pb]VMT-α-NET is designed to target and deliver lead (Pb) to tumor sites expressing somatostatin receptor type 2 (SSTR2) [3] - The company is conducting a multi-center, open-label, dose-escalation, dose-expansion study for patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received prior radiopharmaceutical therapies [3] Group 3: Interim Analysis and Safety Findings - An interim analysis reported at the ASCO-GI in January 2026 included safety data from 56 patients, with no dose limiting toxicities or serious treatment-related complications reported [4][5] - Among the 56 patients, 21 (37.5%) experienced Grade 3 or higher treatment-emergent adverse events, with one patient experiencing a transient Grade 4 event [6][7] Group 4: Efficacy Data - Updated efficacy analysis indicated that 19 of 25 patients (76%) were without progression and remained alive, including both patients in Cohort 1 [8] - In Cohort 2, 9 patients (39%) showed a response according to investigator-assessed RECIST v1.1, with 8 (35%) of those responses confirmed [8] Group 5: Company Overview - Perspective Therapeutics, Inc. specializes in radiopharmaceutical development, utilizing proprietary technology to deliver alpha-emitting isotopes specifically to cancer cells [9] - The company is also developing complementary imaging diagnostics to personalize treatment and optimize patient outcomes through a "theranostic" approach [9] - The company's ongoing programs include neuroendocrine tumors, melanoma, and solid tumors, all in Phase 1/2a trials in the U.S. [10]